Contrast-Enhanced mammography: sharper images to catch hidden breast cancers?

NCT ID NCT04871139

Ongoing Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether contrast-enhanced mammography (CEM) — a mammogram with an iodine dye injection — can find breast cancer more accurately than standard mammography. Researchers will compare CEM with other imaging methods in 100 women who have suspicious breast findings and need a biopsy. The goal is to see if CEM helps doctors target the most concerning areas for biopsy, potentially improving cancer detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iodine-based contrast agent
What this could lead to: If successful, CEM could become a more accurate imaging tool to detect breast cancer and guide biopsies, potentially reducing missed cancers.
What could go wrong: This is a small, early-phase study (100 participants) at a single center. The technique may not prove significantly better than current methods, and iodine contrast carries a small risk of allergic reaction or kidney strain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.